VEGF-antagonism and Endothelial Function in Age-related Macular Degeneration (AMD)

Sponsor
University of Zurich
Study ID
NCT00727753
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Ranibizumab — DRUG
    ranibizumab (0.5 mg) will be injected intraocular
  • Bevacizumab — DRUG
    Bevacizumab (1.25 mg) will be injected intraocular
  • No treatment — OTHER
    No treatment

Study Details

The objective of this study is to evaluate the effects of 2 intravitreal injections with Ranibizumab or Avastin on endothelial function in subjects with neovascular macular degeneration compared to patients with dry AMD.

Key Dates

First listed
Aug 4, 2008
Start date
Jul 31, 2008
Status verified
May 2015
Primary completion
Dec 31, 2012
Completion
Oct 31, 2013

Study Design

Enrollment
54 participants (actual)

Arms

  • Arm: Ranibizumab
  • Arm: Bevacizumab
  • Arm: Dry AMD

Primary Outcome Measure

Change of endothelial function after 2 intravitreal injections and 8 weeks follow-up with ranibizumab or bevacizumab in patients with neovascular macular degeneration compared to patients with dry AMD. [ Time Frame: 8 weeks ]

Related Studies